FDA-mandated clinical holds, strategic partnership breakups and $800 million biotech acquisitions. In this episode of the Xtalks Life Science Podcast, Sarah revisits two Parkinson’s biotech companies — Prevail Therapeutics and Voyager Therapeutics — to see what progress they’ve made in their gene therapy clinical development programs since April 2019. She shares how well the firms have weathered the COVID-19 pandemic, and the team discusses the outlook for the drug development industry in general.
Also in this episode, Ayesha explores the link between Parkinson’s disease and melanoma, and how gene therapies could target both. The team discusses the disconnect between basic, academic research and applied research in industry, and how funding is at the heart of the problem.
Read the full articles here:
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.